Free Trial

Oxford Biomedica (OXB) Competitors

Oxford Biomedica logo
GBX 299 -5.00 (-1.64%)
As of 04/17/2025 11:56 AM Eastern

OXB vs. ONT, ERGO, SLN, PRTC, HZD, FARN, VRP, ARIX, 4BB, and AVCT

Should you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), 4basebio (4BB), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.

Oxford Biomedica vs.

Oxford Biomedica (LON:OXB) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Oxford Biomedica has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Biomedica£98.31M3.23-£143.51M-£134.59-2.22
Oxford Nanopore Technologies£184.78M5.96-£175.21M-£18.58-6.24

Oxford Biomedica currently has a consensus price target of GBX 560, suggesting a potential upside of 87.29%. Oxford Nanopore Technologies has a consensus price target of GBX 233.33, suggesting a potential upside of 101.24%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Oxford Nanopore Technologies
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

64.1% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 38.4% of Oxford Nanopore Technologies shares are owned by institutional investors. 21.2% of Oxford Biomedica shares are owned by insiders. Comparatively, 32.6% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oxford Biomedica received 325 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote.

CompanyUnderperformOutperform
Oxford BiomedicaOutperform Votes
359
66.73%
Underperform Votes
179
33.27%
Oxford Nanopore TechnologiesOutperform Votes
34
100.00%
Underperform Votes
No Votes

Oxford Nanopore Technologies has a net margin of -94.82% compared to Oxford Biomedica's net margin of -145.98%. Oxford Nanopore Technologies' return on equity of -26.02% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Biomedica-145.98% -202.50% -12.67%
Oxford Nanopore Technologies -94.82%-26.02%-14.42%

In the previous week, Oxford Nanopore Technologies had 8 more articles in the media than Oxford Biomedica. MarketBeat recorded 10 mentions for Oxford Nanopore Technologies and 2 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 0.60 beat Oxford Biomedica's score of -0.39 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oxford Biomedica
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oxford Nanopore Technologies
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oxford Biomedica has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Oxford Nanopore Technologies has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Summary

Oxford Nanopore Technologies beats Oxford Biomedica on 12 of the 18 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OXB vs. The Competition

MetricOxford BiomedicaBiotechnology IndustryMedical SectorLON Exchange
Market Cap£317.84M£117.15M£5.29B£2.47B
Dividend Yield4.57%3.69%5.11%4.95%
P/E Ratio-2.223.0321.71129.48
Price / Sales3.234,018.62379.10231,299.35
Price / Cash3.0113.0138.1527.98
Price / Book4.4233.196.434.44
Net Income-£143.51M-£87.82M£3.21B£5.80B
7 Day Performance6.98%3.31%5.23%3.14%
1 Month Performance2.05%-6.28%-9.53%3.82%
1 Year Performance58.20%84.46%10.95%102.57%

Oxford Biomedica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OXB
Oxford Biomedica
2.3372 of 5 stars
GBX 299
-1.6%
GBX 560
+87.3%
+58.2%£317.84M£98.31M-2.22891Gap Down
ONT
Oxford Nanopore Technologies
2.1217 of 5 stars
GBX 105.21
+6.9%
GBX 227.50
+116.2%
+17.2%£998.45M£184.78M-5.661,281News Coverage
Gap Up
High Trading Volume
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
PRTC
PureTech Health
1.8467 of 5 stars
GBX 117.20
-15.2%
GBX 455
+288.2%
-41.0%£352.05M£521,320.79-4.81300Gap Down
High Trading Volume
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
FARN
Faron Pharmaceuticals Oy
N/AGBX 223
+3.7%
N/A+77.0%£299.38MN/A-5.9634News Coverage
High Trading Volume
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
4BB
4basebio
N/AGBX 1,204
+2.0%
GBX 1,600
+32.9%
+6.6%£154.23M£311,000.00-1,543.59101Gap Down
AVCT
Avacta Group
N/AGBX 38.05
+7.2%
N/A-28.1%£144.56M£26.29M-4.90120Gap Up

Related Companies and Tools


This page (LON:OXB) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners